Other News To Note
Tuesday, June 12, 2012
Gilead Sciences Inc., of Foster City, Calif., said the FDA extended the PDUFA date to Sept. 14 for the priority review of Truvada (emtricitabine/tenofovir disoproxil fumarate) to prevent HIV infection in high-risk adults.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.